ArticleHemaSphere2026

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.

David Belada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.